Cellectis ( Cellectis)

Primary tabs

Cellectis's picture

Management

Contact Address

About Cellectis

Cellectis a biopharmaceutical company focused on developing immunotherapies based on genome-edited CAR T-cells (UCARTs).[1] Cellectis was founded in 1999 and designs novel products including immune therapies for cancer and enzymes which can add DNA at targeted places in genomes.

Cellectis press release, blog etc

Mon, 12/08/2025 - 05:57 ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Wed, 11/19/2025 - 08:21 Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
Tue, 10/07/2025 - 07:05 Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
Fri, 06/27/2025 - 06:08 Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
Tue, 04/29/2025 - 07:15 Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Mon, 02/24/2025 - 06:05 Cellectis Presents Smart CAR T Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Tue, 08/27/2024 - 04:21 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Wed, 08/07/2024 - 23:51 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Sat, 08/03/2024 - 08:57 FDA Grants Orphan Drug Designation to Cellectis CLLS52 (alemtuzumab) For ALL Treatment
Thu, 07/25/2024 - 17:58 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Thu, 06/20/2024 - 19:39 Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
Wed, 06/12/2024 - 23:09 Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Wed, 06/05/2024 - 02:04 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
Wed, 12/21/2022 - 20:05 Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
Thu, 11/10/2022 - 07:11 Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN and TALE Base Editors (TALE-BE)
Mon, 10/10/2022 - 20:58 Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
Wed, 10/05/2022 - 18:08 Cellectis to Present Pre-Clinical Data on TALEN-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting
Mon, 01/10/2022 - 01:17 Cellectis Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
more

InfoBox

HomePagewww.Cellectis.com
Facebookwww.facebook.com/cellectis
Twittertwitter.com/cellectis
Wikipediaen.wikipedia.org/wiki/Cellectis